Focal Segmental Glomerulosclerosis (FSGS) is a very hard condition to treat
and it is not so sensitive to some medicines and hormone as other kidney
diseases. Even if it is controlled temporarily, it is very likely to relapse.
After its diagnosis, it may develop into Renal Failure in several years. After
ESRF patients develop to ESRF, kidney transplant become one choice.
Risk factors:
The risk of FSGS recurring in the new transplanted kidney varies from
20%~50%. Usually, the relapse occurs very soon after the surgery, within hours
to days. In most cases, this will be within the first year after kidney
transplantation.
The relapse rate after kidney transplant
Unfortunately, though the mortality rate associated with ESRD can be
partially improved by kidney transplant, lots of patients with FSGS tend to lose
the transplanted organ due to the relapse of this disorder. Actually, relapse
rates as high as 80% has been reported.
In fact, the main reason is the autoimmune process can not be corrected and
recover normal. Therefore, the immune system will attack the kidney tissues and
cells again thus resulting in the returning of the disease. How to avoid FSGS
relapse after kidney transplant?
Immunotherapy is a treatment that use the body’s own immune system to help
fight against the disease. The concept of immunotherapy is based on the body’s
natural defense system, which protects us against a variety of diseases.
Immunotherapy is used to treat FSGS in China for years, and more importantly, it achieves significant success already. The
Immunotherapy we adopted is not a single therapy, but multiple.